A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 162 participants.
Also called NCT07448038
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 162 participants
- Sponsor
- Registry
-
NCT07448038
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Canada
- Registry status
- Recruiting
Technical summary
Registry record NCT07448038. Randomized; quadruple masking; primary purpose treatment. Start 2026-06-05 (actual); primary completion 2028-01-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
- Acronym
- RIVULET
- Condition
- Atherosclerosis
- Intervention (Drug)
- Selnoflast
- Intervention (Drug)
- Placebo
- Lead sponsor
- Genentech, Inc.
Record details
- Record id
cardio:ct-nct07448038- Content hash
8c4a46cda6b972fa1e8a7227d63845610b303bb9b1bc185283e7365e9b096998